This NDC is on FDA's drug shortage list (posted Jul 18, 2023)
Product Information
SAXENDA 18 MG/3 ML PEN is a brand product labeled by Novo Nordisk, priced at $87.1370 per ML under NDC 00169280015. Its NADAC has been published 562 times since Nov 18, 2015.
FDA first approved this application on Dec 23, 2014. Its Orange Book therapeutic-equivalence code is AP2.
The High Outlier badge above means this manufacturer's average price in the liraglutide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
6 mg/mL
Manufacturer
Novo NordiskNDC
00169280015
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
8/19/2026
Active Ingredients
LIRAGLUTIDEApproval Type
New Drug (NDA)
FDA Application
NDA206321FDA Approved
12/23/2014
TE Code
AP2
On Market Since
12/31/2014
Pharmacological Classes
Price Statistics
The NADAC for SAXENDA 18 MG/3 ML PEN has been published 562 times since Nov 18, 2015, and over the history we have for it it has risen 25.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $87.1370 per ML |
|---|---|
| All-time high | $87.1688 (Aug 12, 2026) |
| All-time low | $69.2275 (Nov 18, 2015) |
| 52-week high | $87.1688 |
| 52-week low | $86.9482 |
| Median price | $86.2389 |
| Average price | $82.0137 |
| Largest weekly change | +8.0% (Apr 13, 2016) |
| Weeks tracked | 562 |
| Tracking since | Nov 18, 2015 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 63% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of SAXENDA 18 MG/3 ML PEN?
The current National Average Drug Acquisition Cost (NADAC) for SAXENDA 18 MG/3 ML PEN, manufactured by Novo Nordisk, is $87.1370 per ML (NDC 00169280015), effective Aug 19, 2026.
How has the price of SAXENDA 18 MG/3 ML PEN changed over time?
Over the history we have for it, the NADAC for SAXENDA 18 MG/3 ML PEN has risen 25.9%. It has been tracked across 562 weekly CMS publications since Nov 18, 2015.
What are the highest and lowest recorded NADAC prices for SAXENDA 18 MG/3 ML PEN?
Since Nov 18, 2015, the NADAC for SAXENDA 18 MG/3 ML PEN has ranged from a low of $69.2275 (Nov 18, 2015) to a high of $87.1688 (Aug 12, 2026), with a median of $86.2389 per ML.
Are there cheaper alternatives to SAXENDA 18 MG/3 ML PEN?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LIRAGLUTIDE 3-PAK 18 MG/3 ML, is $32.0017 per ML — about 63% below SAXENDA 18 MG/3 ML PEN.
Who manufactures SAXENDA 18 MG/3 ML PEN?
SAXENDA 18 MG/3 ML PEN (NDC 00169280015) is labeled by Novo Nordisk, and CMS classifies it as a brand product.
Is SAXENDA 18 MG/3 ML PEN in shortage?
Yes — NDC 00169280015 is currently listed in FDA's drug shortage database (posted Jul 18, 2023).